RESULTS: The inflammatory lesion count significantly (p ≤ 0. 05) decreased with DC at Day 8 and Day 15; a significant decrease of the non-inflammatory lesion count was observed at Day 15 (p < 0. The total lesion count had significantly (p ≤ 0.
Relevant if you're working with niacinamide, salicylic acid, zinc for acne and aging.
If you're targeting acne, this research supports adding niacinamide to your AM/PM routine. Timeline to expect: 2 weeks based on study duration.
If you're targeting acne, this research supports adding salicylic_acid to your AM/PM routine. Timeline to expect: 2 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
1. J Cosmet Dermatol. 2026 Jan;25(1):e70641. doi: 10.1111/jocd.70641. Rapid and Visible Efficacy of a Dermocosmetic in Acne Patients With Fair Skin Phototypes: Results of a Randomized Split-Face Study. Queille-Roussel C(1), Odeimi J(2), Broallier M(2), Kerob D(2), Tan J(3).
1. J Cosmet Dermatol. 2026 Jan;25(1):e70641. doi: 10.1111/jocd.70641. Rapid and Visible Efficacy of a Dermocosmetic in Acne Patients With Fair Skin Phototypes: Results of a Randomized Split-Face Study. Queille-Roussel C(1), Odeimi J(2), Broallier M(2), Kerob D(2), Tan J(3). Author information: (1)CPCAD, CHU l'Archet, Nice, France. (2)La Roche-Posay, Laboratoire Dermatologique, France. (3)Department of Medicine and Windsor Clinical Research Inc, Western University, Windsor, Canada. INTRODUCTION AND OBJECTIVES: Dermocosmetics have proven their benefit in acne management. However, only very few studies investigated their efficacy kinetics. This study assessed the efficacy kinetics of a dermocosmetic cream (DC) containing Punica granatum Pericarp extract, Salicylic acid, Niacinamide, Zinc gluconate, and Aqua Posae Filiformis in subjects with acne. MATERIAL AND METHODS: 16 subjects (14 women, 2 men; mean age 29.4 ± 7.7 years; phototype II and III) with mild to moderate acne participated in a randomized, intra-individual, split-face study for 15 days. Hemi-faces randomly received DC or remained untreated. Assessments included lesion counts, acne severity, and local tolerance; subjects also rated the perceived benefit of the DC. Efficacy was also evaluated using standardized multi-modality full-face imaging and a mobile connected imaging system. RESULTS: The inflammatory lesion count significantly (p ≤ 0.05) decreased with DC at Day 8 and Day 15; a significant decrease of the non-inflammatory lesion count was observed at Day 15 (p < 0.01). The total lesion count had significantly (p ≤ 0.05) decreased with DC at Day 8 and Day 15. Between-side differences were significant (all p ≤ 0.05) for all lesion types at D15. Local tolerance was good. Most subjects considered that their skin appearance and the visibility of acne lesions had improved. CONCLUSION: This exploratory study provides strong evidence on the efficacy kinetics of a DC cream in acne management in subjects with fair skin tones. It shows that early, daily and specific treatment with a targeted DC significantly improves all acne lesions type, as well as acne severity as soon as 15 days. © 2026 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC. DOI: 10.1111/jocd.70641 PMCID: PMC12766543 PMID: 41487026 [Indexed for MEDLINE] Conflict of interest statement: All authors, apart from C.Q.‐R. and J.T., are employees of La Roche‐Posay Laboratoire Dermatologique. C.Q.‐R. has no conflicts of interest to disclose. J.T. is a consultant and speaker for La Roche Posay Laboratoire Dermatologique, France.
Original source →Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.
Friedreich's ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low cardiopulmonary fitness. We tested the effect of exercise and NAD+ precursor supplementation with nicotinamide riboside, which have each shown benefits in animal and early clinical studies, on cardiopulmonary fitness in individuals with Friedreich's ataxia. This 12-week, outpatient, phase 2, single-site (Children's Hospital of Philadelphia, Philadelphia, PA, USA), randomised, 2 × 2 factorial clinical trial recruited individuals aged 10-40 years with an ejection fraction of 45% or greater who were able to exercise.
Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →